Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi et al.|Journal of Hepato-Biliary-Pancreatic Sciences|2022Cited by 244
Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)Daisuke Sakai, Tatsuya Ioka, Tadatoshi Takayama et al.|Annals of Oncology|2018Cited by 109
Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohortItaru Naitoh, Satoshi Takai, Terumi Kamisawa et al.|Digestive and Liver Disease|2021Cited by 32
HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinomaMasahiro Shitani, Tsuyoshi Hayashi, Yasutoshi Kimura et al.|Scientific Reports|2022Cited by 3
Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS) compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent biliary tract cancer (KHBO1401-MITSUBA).Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi et al.|Journal of Clinical Oncology|2015Cited by 1